Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting

被引:29
作者
Jones, Bruce M. [1 ]
Huelfer, Kathryn [1 ]
Bland, Christopher M. [2 ]
机构
[1] St Josephs Candler Hlth Syst Inc, 5353 Reynolds St, Savannah, GA 31405 USA
[2] Univ Georgia, Coll Pharm, St Josephs Candler Hlth Syst Inc, Savannah, GA USA
关键词
ceftolozane/tazobactam; OPAT;
D O I
10.1093/ofid/ofaa014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Ceftolozane/tazobactam (C/T) is a novel cephalosporin/beta-lactamase inhibitor currently dosed by 8-hour intervals to treat complicated and multidrug-resistant Pseudomonas aeruginosa infections in inpatients. This dosing strategy limits the ability to transition patients to outpatient antimicrobial therapy. There are limited data in the literature to support continuous infusion (CI) dosing. Methods. This study is a retrospective chart review of patients who received CI C/T at an infusion center part of a community health system. Patients were evaluated from August 2016 through January 2018. Patients were included in the study if they were >= 18 years old and received their entire course of C/T as a CI in the outpatient setting. Patients were excluded if they received any part of their therapy as an inpatient. Results. The primary outcome evaluated was symptom resolution. Secondary outcomes evaluated were microbiologic resolution as well as patient satisfaction. Seven patients received either 4.5 or 9 grams of continuous infusion C/T every 24 hours in the outpatient setting over the study period. For the primary outcome, 6 of 7 patients had symptom resolution. For the secondary outcomes, 3 of 3 patients had microbiologic resolution, and patient satisfaction scores were overall positive among respondents. Conclusions. Ceftolozane/tazobactam delivered as a continuous infusion may be a safe, effective, and convenient way to treat infections caused by P aeruginosa. This novel treatment regimen can be an option for patients to avoid hospital admission or discharge to complete therapy as an outpatient.
引用
收藏
页数:3
相关论文
共 9 条
[1]   Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion [J].
Buck, C ;
Bertram, N ;
Ackermann, T ;
Sauerbruch, T ;
Derendorf, H ;
Paar, WD .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (01) :62-67
[2]  
Centers for Medicare & Medicaid Services, HCAHPS PAT PERSP CAR
[3]   Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis [J].
Davis, Sarah Elizabeth ;
Ham, Jared ;
Hucks, Jennifer ;
Gould, Alyssa ;
Foster, Rachel ;
Justo, Julie Ann ;
Nicolau, David P. ;
Bookstaver, P. Brandon .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (08) :501-504
[4]   Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting [J].
Jones, Bruce M. ;
Smith, Bradley ;
Bland, Christopher M. .
ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) :715-716
[5]   Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections [J].
Liscio, Jordan L. ;
Mahoney, Monica V. ;
Hirsch, Elizabeth B. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (03) :266-271
[6]  
Marshall G., 1994, PATIENT SATISFACTION
[7]  
Nateson S, 2016, DETERMINATION ALTERN
[8]   Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program [J].
Stewart, A. ;
Roberts, J. A. ;
Wallis, S. C. ;
Allworth, A. M. ;
Legg, A. ;
McCarthy, K. L. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (06) :941-942
[9]   Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia [J].
Xiao, Alan J. ;
Miller, Benjamin W. ;
Huntington, Jennifer A. ;
Nicolau, David P. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (01) :56-66